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ABSTRACT 
Individuals with anxiety disorders are significantly more likely to develop substance use 
disorders than those without anxiety disorders (Kessler & Greenberg, 2002). Despite a sizeable 
body of literature focused on etiological and maintenance factors underlying the co-occurrence 
of substance use and anxiety pathology, this relationship remains poorly understood. 
Transdiagnostic factors, specifically distress tolerance, anxiety sensitivity, and emotion-driven 
impulse control difficulties, have been posited to contribute to the relationship of anxiety and 
substance abuse, and in particular, nonmedical use of prescription drugs (NMUPD; Dennhardt & 
Murphy, 2013; Wolitzky-Taylor et al., 2015). The current study examined group differences 
among the aforementioned transdiagnostic factors, and whether they served as mediators in the 
relation of anxiety and NMUPD in a sample of college students. Participants were 184 
undergraduate students at the University of Mississippi who either engaged in past year NMUPD 
or did not. All participants completed a battery of questionnaires and participated in a laboratory 
task. Counter to the hypotheses, results indicated that there were not significant differences in the 
transdiagnostic variables among the two groups, and that none of the transdiagnostic variables 
mediated the relation of anxiety and NMUPD. Compared to non-drug users, drug users reported 
more substance use overall, including polysubstance use, and reported more self-medication 
motives for NMUPD than a similar sample of undergraduate students. The findings are 
consistent with the extant literature indicating that college students who engage in past year 
NMUPD are at increased risk for other substance abuse, including simultaneous polysubstance 
use. Future studies should further examine risk factors for NMUPD among college students. 
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1 
INTRODUCTION 
Anxiety disorders represent the most frequently occurring mental health disorders in the 
United States, with a lifetime prevalence rate of 28.8% in the general population (Kessler, Chiu, 
Demler, & Walter, 2005). Anxiety disorders are associated with significant economic burden and 
negative outcomes, such as elevated risk of unemployment, lower income, and shortened 
lifespan (Ettner, Frank, & Kessler, 1997; Jayakody, Danziger, & Kessler, 1998; Kessler & 
Greenberg, 2002). In addition to these adverse consequences, higher rates of alcohol, nicotine, 
and illicit drugs (e.g., cannabis, heroin) have been observed among individuals with anxious 
pathology (Zvolensky & Schmidt, 2004). Indeed, individuals with anxiety disorders are 1.6 to 
3.0 times more likely to develop substance use disorders (SUDs) than individuals without 
anxiety disorders (Kessler & Greenberg, 2002).  
The co-occurrence of anxiety disorders and SUDs is associated with greater symptom 
severity and functional impairment than either disorder alone (Burns, Teesson, & O’Neill, 2005; 
Magidson, Liu, Lejuez, & Blanco, 2012). Furthermore, co-occurring anxiety symptoms and 
substance use have a higher prevalence than anxiety disorders alone (Zahradnik & Stewart, 
2009). Epidemiological studies have found that 11.9% to 14.9% of individuals with anxiety 
disorders have a comorbid SUD, and 17.7% to 33.5% of individuals with SUDs have a 
concurrent anxiety disorder (Grant et al., 2004; Teesson, Slade, & Mills, 2009). Even though 
research has focused on these frequently co-occurring conditions, more information is warranted 
to determine which specific substances pose the greatest threat to individuals with pathological 
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anxiety, and to identify characteristics relevant to anxiety that may amplify problematic 
substance use. 
Both theoretical and empirical evidence support the role of substance abuse as a way to 
manage aversive emotional states and physiological arousal associated with anxiety (Morris, 
Stewart, & Ham, 2005; Robinson, Sareen, Cox, & Bolton, 2011; Smith, Feldner, & Badour, 
2011; Stewart & Conrod, 2008). Specifically, the self-medication hypothesis and tension-
reduction models (herein collectively referred to as the self-medication hypothesis; Comeau, 
Stewart, & Loba, 2001; Conger, 1956; Khantzian, 1985) posit that individuals engage in 
substance misuse to reduce preexisting negative affect, such as anxiety symptoms. This theory is 
based in negative reinforcement, wherein substances are used to reduce anxiety symptoms 
(Davis, Witcraft, Baird, & Smits, 2017; Eissenberg, 2004; Smith et al., 2011). For instance, when 
a person has an unpleasant internal experience, such as anxious arousal, distress, or negative 
affect, s/he might engage in substance use (e.g., alcohol) to reduce the anxiety. Repeated over 
time, this process creates a learning experience that drinking alcohol reduces anxiety; in other 
words, drinking alcohol is negatively reinforced by the reduction in anxiety. However, when the 
substance’s short-term effects subside, the chances of the person craving alcohol and drinking 
alcohol to reduce anxiety is increased due to it being an effective anxiety-reduction strategy in 
the individual’s learning history (Hayes, Wilson, Gifford, Follette, & Strosahl, 1996). Therefore, 
this negative reinforcement cycle leads to long-term increases in frequency and intensity of 
problematic substance use (Eissenberg, 2004; Khantzian, 1985).  
In addition to the self-medication hypothesis literature, there is a growing body of 
empirical and theoretical work that suggests the relation between anxiety and substance misuse 
may be explained by common third variables or transdiagnostic factors (Tull, Baruch, Duplinsky, 
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& Lejuez, 2008; Wolitzky-Taylor et al., 2015). Specifically, distress tolerance, anxiety 
sensitivity, and emotion-driven impulse control difficulties have been found to each play a role 
in the anxiety-substance abuse link (Allan, Macatee, Norr, Raines, & Schmidt, 2015; Howell, 
Leyro, Hogan, Buckner, & Zvolensky, 2010; Kaiser, Milich, Lynam, & Charnigo, 2012; Stewart 
& Kushner, 2001). First, distress tolerance describes the perceived ability or inability to 
withstand distress and/or other negative emotional states (Simons & Gaher, 2005). Distress 
tolerance has been associated with increased symptom severity across symptoms of panic 
disorder, social anxiety disorder, obsessive-compulsive disorder, and anxious worry above and 
beyond their relationship with general negative affect (Keough, Riccardi, Timpano, Mitchell, & 
Schmidt, 2010). Additionally, individuals who have decreased levels of distress tolerance (i.e., 
intolerant of distress) are posited to engage in substance use to cope with negative affective 
states, such as anxiety (Wolitzky-Taylor et al., 2016). For instance, Howell and colleagues 
(2010) found that distress tolerance was uniquely related to coping-oriented motives for alcohol 
use among young adult drinkers.  
Although research in this area has primarily relied on self-report measures of distress 
tolerance, a few studies have demonstrated that behavioral assessments of distress tolerance are 
associated with negative affect and substance use. For example, Gorka and colleagues (2012) 
used a behavioral measure of distress tolerance to investigate the role of distress tolerance in the 
relation of problematic alcohol use and negative affect, finding that negative affect predicted 
alcohol use problems in individuals with low, but not high, distress tolerance. Similarly, 
Vujanovic and colleagues (2016) found that self-report and behavioral assessments of distress 
tolerance were significantly correlated with posttraumatic stress disorder symptoms, above and 
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beyond past month substance use, among participants who had experienced a potentially 
traumatic event.  
The second transdiagnostic factor important to the anxiety-substance abuse link is anxiety 
sensitivity, which refers to the trait-like fear that the experience of anxiety will result in 
catastrophic consequences, such as panic, illness, or social embarrassment (Reiss, Peterson, 
Gursky, & McNally, 1986). Of note, factor analytic evidence suggests that distress tolerance and 
anxiety sensitivity are related, yet distinct, as distress tolerance encompasses a wider range of 
aversive states (e.g., sadness, anger) and maladaptive reactions to distress (e.g., behavioral, 
emotional; Bernstein, Zvolensky, Vujanovic, & Moos, 2009; Howell et al., 2010; Wolitzky-
Taylor et al., 2015). Extensive empirical and theoretical research have established anxiety 
sensitivity as a transdiagnostic factor across many psychopathologies, including anxiety and 
problematic substance use (Boswell et al., 2013; Tull et al., 2008).  
Numerous studies support the unique role of anxiety sensitivity in explaining the co-
occurrence of anxiety and SUDs (Stewart & Kushner, 2001). For instance, Dixon and colleagues 
(2014) found that high anxiety was positively associated with illicit substance abuse in 
individuals with elevated anxiety sensitivity, but not in those with nonclinical levels of anxiety 
sensitivity, suggesting that trait anxiety alone does not predict substance abuse. Consistent with 
the self-medication hypothesis, anxiety sensitivity has been associated with increased substance 
abuse frequency among inpatients with anxiety disorders (DeHaas, Calamari, & Bair, 2002), and 
has been linked to coping-related motives for alcohol (Berenz et al., 2016), cannabis (Bonn-
Miller, Zvolensky, & Bernstein, 2007), and nicotine (Gonzalez, Zvolensky, Vujanovic, Leyro, & 
Marshall, 2008). In addition, anxiety sensitivity has been found to be integrally involved in the 
relation of anxiety and substance misuse. One prospective study found that anxiety sensitivity 
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uniquely predicted the development of alcohol use disorders over and above trait anxiety, 
indicating that anxiety sensitivity may play a bigger role in the misuse of alcohol than anxiety 
alone (Schmidt, Buckner, & Keough, 2007).  
Lastly, emotion-driven impulse control difficulties refer to the propensity to engage in 
undesired behavior, such as substance abuse and risky sex, when experiencing negative emotions 
(Gratz & Roemer, 2004; Weiss, Tull, Anestis, & Gratz, 2013; Whiteside & Lynam, 2001). 
Emotion-related impulsivity has been associated with anxiety, avoidance of anxiety, and 
substance abuse (Acton, 2003; Weiss et al., 2013; Wolitzky-Taylor et al., 2015). With regard to 
anxiety pathology, studies have found that negative urgency, or impulsivity driven by negative 
affect, is associated with increased worry (Pawluk & Koerner, 2013), obsessions (Cougle, 
Timpano, & Goetz, 2012), and increased engagement in risky behaviors among both anxious and 
nonclinical samples (Guillot, Pang, & Leventhal, 2014; Weitzman, McHugh, & Otto, 2011). 
Studies suggest that individuals with substance use disorders tend to use maladaptive emotion 
regulation strategies, and have more emotion regulation deficits overall than those who do not 
abuse substances (Fox, Axelrod, Paliwal, Sleeper, & Sinha, 2007; Fox, Hong, & Sinha, 2008; 
Weiss et al., 2013). Additionally, it has been hypothesized that during emotional states, impulse 
control may fail as a result of giving primacy to affect regulation during states of being 
emotionally distraught (Tice, Bratslavsky, & Baumeister, 2001). For instance, following a sad 
mood induction, when participants are not instructed that their mood will be stagnant, then they 
tend to eat increased amounts of fatty foods in response to distress because they expect that 
doing so will make them feel better (i.e., negative reinforcement; Tice et al., 2001). 
Emotion-driven impulse control difficulties have been posited to have a causal 
relationship with substance use, wherein increases in uninhibited impulsivity lead to increases in 
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substance use during highly emotional states (Smith & Cyders, 2016). Prior studies have found 
that elevated negative urgency is linked to increased cannabis use (Kaiser et al., 2012), nicotine 
use (Guillot et al., 2014), and alcohol use (Menary et al., 2015). Additionally, negative urgency 
has been found to moderate the relationship between anxiety sensitivity and smoking cessation 
outcomes and abstinence expectancies (Guillot et al., 2014), as well as the effect of anxiety on 
alcohol dependence (Menary et al., 2015).  
Several investigations have examined distress tolerance, anxiety sensitivity, and emotion-
driven impulse control difficulties in attempt to better understand anxiety and substance use. For 
example, results from an empirical study investigating marijuana use suggest that both distress 
tolerance and anxiety sensitivity contribute to different self-medication motives for use, as both 
distress tolerance and anxiety sensitivity were related to coping-oriented motives, but only 
anxiety sensitivity was related to conformity-oriented motives (Zvolensky et al., 2009). Another 
study found that negative urgency accounted for significant variance in the relation between 
anxiety sensitivity and smoking behaviors, suggesting that smokers high in anxiety sensitivity 
are likely to react impulsively when experiencing negative affect compared to those lower in 
anxiety sensitivity (Guillot et al., 2014). Lastly, a study examining substance use, distress 
tolerance, and negative urgency in a sample of first-year college students found that only 
negative urgency was significantly associated with all substance use outcomes (i.e., alcohol, 
marijuana, tobacco, and illicit drugs), above and beyond trait negative affect (Kaiser et al., 2012). 
Taken together, these findings further inform the self-medication model and suggest that distress 
tolerance, anxiety sensitivity, and emotion-driven impulse control difficulties importantly 
influence substance use. Unfortunately, the literature in this area is underdeveloped and few 
studies have simultaneously examined these constructs in relation to anxiety and substance use.  
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To date, only one study has concurrently examined the impact of distress tolerance, 
anxiety sensitivity, and negative emotion-driven impulsivity on alcohol and cannabis use in 
adolescents (Wolitzky-Taylor et al., 2016). This study demonstrated that negative emotion-
driven impulsivity was the only significant, unique mediator in the relationship between anxiety 
pathology and alcohol and cannabis use, after accounting for the effects of distress tolerance and 
anxiety sensitivity (Wolitzky-Taylor et al., 2016). That is, higher levels of anxiety symptoms 
were associated with greater alcohol-use and cannabis-use problems, respectively, through 
increased impulsivity (Wolitzky-Taylor et al., 2016). These findings suggest that emotion-driven 
impulse control difficulties may be particularly important in the relation between anxiety and 
problematic substance use. 
Research has primarily focused on understanding the associations between anxiety 
pathology and alcohol and nicotine use, with fewer studies examining illicit substance (e.g., 
marijuana, heroin) and prescription medication abuse (Zvolensky & Schmidt, 2004). Notably, 
prescription drug abuse is a rapidly increasing problem among adolescents and adults across the 
world. Throughout the past ten years, the 12-month prevalence rate of abuse and dependence of 
prescription drugs increased 67% (Blanco et al., 2007), which is largely a result of illegal use 
rather than medical use (Arria & DuPont, 2010; Wu & Blazer, 2011; Young, Glover, & Havens, 
2012). Indeed, the 2011 National Survey on Drug Use and Health (NSDUH) indicated that 6.1 
million people aged twelve and older had used prescription drugs recreationally within the 
previous month (Substance Abuse and Mental Health Services Administration [SAMHSA], 
2015). Over this span of time, prescription drug abuse has come to represent a significant 
economic burden (Birnbaum et al., 2006; Hansen, Oster, Edelsberg, Woody, & Sullivan, 2011), 
and has been associated with a range of adverse outcomes including incarceration (Serxner, 
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Gold, & Bultman, 2001), absenteeism (Birnbaum et al., 2006), and even death (Van Hasselt, 
Keyes, Bray, & Miller, 2015).  
The nonmedical use of prescription drugs (NMUPD) occurs when prescription 
medications are obtained from a nonmedical source (e.g., a classmate), not taken as prescribed 
(e.g., more than the prescribed dosage), or used for a nonmedical or recreational purpose (e.g., to 
get high, to stay up later; Kelly, Rendina, Vuolo, Wells, & Parsons, 2015). The major categories 
of frequently abused prescription drugs are stimulants (e.g., amphetamines), opioid pain relievers 
(e.g., Oxycodone), and sedatives (e.g., anxiolytics; National Institute on Drug Abuse [NIDA], 
2011). Holloway and Bennett (2012) posit two types of prescription drug misuse: 1) using a 
prescribed medication in a way that was not intended; and 2) using prescription drugs that are 
sold, traded, or given away. One study found that 17% of adolescents sold, traded, or gave away 
their prescription, while 12% kept their prescription but used it in a way in which it was not 
prescribed. In total, 40% of students reported some combination of the aforementioned misuse 
(Holloway & Bennett, 2012). Consistent with these findings, another study found that 14.7% of 
students reported giving their prescribed stimulant to friends (Poulin, 2001). 
Although NMUPD is at an all-time high across all age groups, adolescents and young 
adults (collectively referred to as youth) are especially vulnerable to misusing prescription 
medication, largely because of the misconception that they are safe to abuse due to their 
prescribed nature (Arria & DuPont, 2010; Wu & Blazer, 2011; Young et al., 2012). Indeed, a 
study examining substance use patterns over the course of ten years indicated that the significant 
increase in NMUPD is most notable among young adults between the ages of 18 and 34 (Blanco 
et al., 2007). In 2013, the percentage of adolescents who reported recreational use of prescription 
drugs on at least one occasion was approximately one-in-four, which is a 33% increase from 
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2008 (NIDA, 2013). In addition, national survey data indicated that of individuals aged 18 – 25, 
44% reported using prescription drugs and 15% reported misuse of prescription drugs in the past 
year (SAMHSA, 2015). Prescription drugs are also quickly becoming one of the most commonly 
used illicit drugs. On college campuses, NMUPD is second only to marijuana use (Grant et al., 
2004; Johnston, O’Malley, & Bachman, 2003), and NMUPD has increased four times more than 
cannabis use disorders over the course of ten years (Blanco et al., 2007).   
The increase in the rates of NMUPD among youth has been attributed to the over-
prescribing of prescription drugs and the ease of access (Centers for Disease Control and 
Prevention [CDC], 2014; NIDA, 2013). Adolescents falsely believe that these drugs are safer 
than illicit drugs because they are prescribed by medical professionals (Netemeyer, Burton, 
Delaney, & Hijjawi, 2015), which may pose dangerous, unanticipated risks, such as negative side 
effects and interactions with other substances (e.g., alcohol; McCabe, Boyd, & Teter, 2009). 
Elevated levels of anxiety symptoms have been posited as a significant vulnerability of NMUPD 
in youth (Blanco et al., 2007; Hall, Howard, & McCabe, 2010; McCabe et al., 2009; Viana et al., 
2012). Data collected from over 43,000 individuals found that those with a history of an anxiety 
disorder were more likely to develop NMUPD than those without a history of anxiety (Blanco et 
al., 2007). Similarly, one study found that individuals with clinically significant levels of panic 
and social anxiety symptoms were two times more likely to be at risk for NMUPD than those 
with nonclinical symptoms (Viana et al., 2012). In another study, health anxiety was shown to be 
a risk factor for NMUPD (Jeffers et al., 2015). At the same time, negative emotion-driven 
impulsivity has been shown to be associated with illicit substance use among college students 
(Kaiser et al., 2012). Specifically, Blanchard and colleagues (2017) found that females reporting 
NMUPD, both over the lifetime and within the past month, had significantly higher rates of 
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negative emotion-driven impulsivity than those who did not report NMUPD. Together these 
studies suggest that anxiety and related vulnerability factors may play a key role in NMUPD.  
Given the increasing rates of NMUPD among youth, college students are a particularly 
important population for informing risk prevention and intervention programs (Arria & DuPont, 
2010; Blanco et al., 2007; Wu & Blazer, 2011; Young et al., 2012). College students present as a 
uniquely vulnerable population due to the high rates of anxiety (Eisenberg, Gollust, Golberstein, 
& Hefner, 2007), polysubstance drug abuse (Arria et al., 2008; McCabe, Teter, Boyd, Knight, & 
Wechsler, 2005), and easy access to substances (Gliksman, 1988) that may occur at higher rates 
in college as compared to other times throughout one’s life. Further, Blanchard and colleagues 
(2017) found that emotion-related impulsivity differentially predicted nonmedical use of 
depressants among college students. Accordingly, the purpose of the current study is to compare 
transdiagnostic anxiety factors (i.e., distress tolerance and anxiety sensitivity) and emotion-
driven impulse control difficulties between college students with and without NMUPD in the 
past year.  
Aim 1: To examine anxiety, trait variables, NMUPD, and related factors among a 
sample of college students.  
Hypothesis 1: NMUPD will be significantly positively associated with trait anxiety, distress 
tolerance, anxiety sensitivity, and emotion-driven impulse control difficulties.  
Hypothesis 2: Compared to individuals without past-year NMUPD, individuals with a 
history of NMUPD will report significantly higher levels of anxiety, anxiety sensitivity, and 
emotion-driven impulse control difficulties, and significantly lower levels of distress tolerance. 
Additionally, reporters of NMUPD are expected to endorse more adverse outcomes that have 
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been associated with NMUPD, such as stressful events, self-medication motives, and frequency 
and diversity of substance use (Arria et al., 2008; McCabe et al., 2005, 2009). 
Hypothesis 3: This study seeks to examine Wolitzky-Taylor et al.’s (2016) mediation 
model in a cross-sectional sample of college students by examining the role of distress tolerance, 
anxiety sensitivity, and emotion-driven impulse control difficulties in the relation between 
anxiety and NMUPD. Wolitzky-Taylor and colleagues (2016) found a significant indirect effect 
of negative emotion-driven impulsivity, but not distress tolerance and anxiety sensitivity, in the 
relation between anxiety and substance misuse. Given prior work among college students (Ali, 
Ryan, Beck, & Daughters, 2013; Berenz et al., 2016), it is expected that anxiety will be indirectly 
associated with NMUPD through distress tolerance (both self-reported and behaviorally 
measured), anxiety sensitivity, and emotion-driven impulse control difficulties. Furthermore, in 
line with the extant literature (e.g., Guillot et al., 2014; Kaiser et al., 2012; Wolitzky-Taylor et 
al., 2016), it is also predicted that the indirect effect of emotion-driven impulse control 
difficulties will be more robust as compared to the indirect effects of distress tolerance and 
anxiety sensitivity in the relation between anxiety and NMUPD.
12 
 
METHOD 
Participants 
Participants were 184 (Mage = 18.85, 75.5% female) undergraduate students who were 
primarily in their freshman year of college (71.2%) recruited from the Department of 
Psychology’s Sona Systems pool of undergraduate students at the University of Mississippi, a 
large, southeastern public university. Participants were 71.7% White, 16.8% Black or African 
American, 6.0% Asian, 3.8% biracial, and 1.6% other. Only 4.3% of participants identified as 
Hispanic or Latino. All individuals who fell outside of the age range of 18 to 25 (i.e., emerging 
adulthood) were excluded from the study (Arnet, 2000). Otherwise, participants were eligible. 
Measures 
The Alcohol Use Disorders Identification Test (AUDIT). The AUDIT (Babor, 
Higgins-Biddle, Saunders, & Monteiro, 2001) is a 10-item self-report questionnaire developed 
by the World Health Organization to screen for harmful and hazardous alcohol use. Items are 
rated on a 5-point Likert scale from 0 to 4, with higher scores indicating more frequent use and a 
broader domain of interference. A clinical cutoff value of eight distinguishes hazardous drinking 
from more serious harmful drinking. The AUDIT has three subscales: hazardous alcohol use 
(e.g., “how many drinks containing alcohol do you have on a typical day when you are 
drinking?”), symptoms of dependence (e.g., “how often during the last year have you found that 
you were not able to stop drinking once you had started?”), and harmful alcohol use (e.g., “have 
you or someone else been injured as a result of your drinking?”). The AUDIT has demonstrated 
good construct validity via its correlation with alcohol use risk factors, reasons for drinking,
13 
 
 negative affect, and withdrawal symptoms (Bohn, Babor, & Kranzler, 1995). Additionally, the 
AUDIT is able to differentiate alcoholics from non-alcoholics, and demonstrates superior 
discriminant ability over and above the Michigan Alcoholism Screening Test (Bohn et al., 1995). 
In the current study, the AUDIT demonstrated adequate reliability (Cronbach’s α = 66). See 
Appendix A for the AUDIT. 
Anxiety Sensitivity Index – 3 (ASI-3). The ASI-3 (Taylor et al., 2007) is an 18-item 
self-report measure of anxiety sensitivity severity and frequency. Anxiety sensitivity is measured 
on a 5-point Likert scale from 0 (“very little”) to 4 (“very much”). The ASI-3 assesses the 
potential catastrophic physical, cognitive, and social consequences of anxiety. The suggested 
clinical cutoff for the ASI-3 is a total score of 23, which indicates clinically significant levels of 
anxiety sensitivity, and suggests impairment or distress due to symptoms (Allan, Korte, Capron, 
Raines, & Schmidt, 2014; Allan, Raines, et al., 2014). The ASI-3 subscales have demonstrated 
good convergent and divergent validity, as they have been shown to be highly correlated with the 
original Anxiety Sensitivity Index, such that correlations among similar subscales were 
significantly larger compared to correlations among dissimilar subscales (Taylor et al., 2007). 
The ASI-3 further demonstrates convergent and divergent validity by its ability to distinguish 
individuals with general anxiety and depressive symptoms (high associations) from those with 
psychosis and self-harming behaviors (low associations) in a sample of highly comorbid 
individuals (Rifkin, Beard, Hsu, Garner, & Björgvinsson, 2015). The ASI-3 has demonstrated 
good to excellent internal consistency overall (Cronbach’s α = .93) in both clinical and 
undergraduate samples (Wheaton, Deacon, McGrath, Berman, & Abramowitz, 2012). However, 
in the current study, the ASI-3 demonstrated poor reliability (α = .58). See Appendix B for the 
ASI-3. 
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College Student’s Stressful Event Checklist (CSSEC). The CSSEC (Holmes & Rahe, 
1967) is a self-report measure of the presence of 32 stressful events experienced by college 
students. Participants place an “X” beside events that they have experienced or events that they 
expect to occur soon. Each event has a predetermined rank and corresponding value (20 to 100, 
20 being the lowest ranked event and 100 being the highest ranked event) that reflects the 
severity of the event. For example, “death of a close family member” is ranked number one and 
assigned the highest value of 100, while “minor traffic violations” is ranked 32 and assigned the 
lowest value of 20. All event values are summed for a total score, which indicates mild (< 150), 
moderate (150 to 300), or severe (> 300) stress. The CSSEC is adapted from Holmes and Rahe’s 
(1967) Social Readjustment Rating Scale (SRRS), which is designed for an adult population, and 
as such the items are tailored to adulthood stressors (e.g., divorce, fired at work, son or daughter 
leaving home). The original SRRS evidenced adequate interrater reliability (Kendall’s 
coefficient of concordance = 0.48; Holmes & Rahe, 1967). In the present study, the CSSEC 
demonstrated adequate internal consistency (α = .74). See Appendix C for the CSSEC. 
Depression Anxiety Stress Scale – 21 (DASS-21). The DASS-21 (Lovibond & 
Lovibond, 1995) is a 21-item self-report measure of symptoms associated with depression, 
anxiety, and stress. Items are rated on a 4-point Likert scale from 0 (“did not apply to me at all”) 
to 3 (“applied to me very much, or most of the time”), with higher scores indicating greater 
levels of distress. The DASS-21 is adapted from the 42-item DASS, and as such, scores on the 
21-item version are doubled so as to make interpretation equivalent across the two versions. The 
anxiety subscale (e.g., “I experienced trembling (e.g., in the hands)”) measures physiological 
symptoms of anxiety, while the stress subscale (e.g., “I found myself getting agitated”) measures 
cognitive symptoms of anxiety. The current study only used the 7-item anxiety subscale of the 
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DASS-21. The DASS-21-Anxiety has displayed good psychometric properties in individuals 
diagnosed with an anxiety or depressive disorder, by demonstrating good internal consistency (α 
= .87) and concurrent validity (Antony, Bieling, Cox, Enns, & Swinson, 1998). In the current 
study, the DASS-21-Anxiety evidenced adequate internal consistency (α = .68). See Appendix D 
for the DASS-21-Anxiety. 
Difficulties in Emotion Regulation Scale (DERS). The DERS (Gratz & Roemer, 2004) 
is a 36-item self-report measure of emotion regulation difficulties. Items are rated on a 5-point 
Likert scale from 1 (“almost never”) to 5 (“almost always”), with higher scores indicating more 
difficulties regulating emotions. The DERS consists of six subscales, including nonacceptance of 
emotional responses, difficulties engaging in goal-directed behavior, impulse control difficulties, 
lack of emotional awareness, limited access to emotion regulation strategies, and lack of 
emotional clarity. In the current study, the 6-item impulse control difficulties subscale (DERS-
Impulse) was used as a measure of emotion-driven impulse control difficulties. Test-retest 
reliability for the DERS-Impulse was adequate (ρ = .57) in a sample of undergraduate students 
(Gratz & Roemer); however, the test-retest sample only consisted of 21 participants, which 
might account for low reliability. Further, the DERS-Impulse has demonstrated good predictive 
validity (Gratz & Roemer, 2004) and has been positively associated with other measures of 
emotion-driven impulse control difficulties (r = .64; Weiss et al., 2013). In the current study, the 
DERS-Impulse evidenced adequate internal consistency (α = .68). See Appendix E for the 
DERS-Impulse. 
Distress Tolerance Scale (DTS). The DTS (Simons & Gaher, 2005) is a 15-item self-
report measure of distress tolerance, or the perceived ability to handle distress. Raters indicate to 
what extent they agree with each item on a 5-point Likert scale from 1 (“strongly agree”) to 5 
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(“strongly disagree”), with higher scores indicating greater ability to tolerate distress. The DTS is 
comprised of four subscales: tolerance (perceived ability to tolerate and endure emotions), 
absorption (attention that is occupied by emotions), appraisal (assessment of emotions as 
acceptable), and regulation (perceived ability to manage emotions). Further, Simons and Gaher 
(2005) found that the DTS demonstrated good divergent validity, as it is negatively associated 
with measures of affective distress (r = -.59) and affective lability (r = -.52). Additionally, the 
DTS was positively correlated with measures of mood acceptance (r = .47) and negative mood 
regulation (r = .54), indicating convergent validity (Simons & Gaher, 2005). Lastly, the DTS has 
also been shown to be negatively related to measures of alcohol and marijuana use, such that 
increased distress tolerance was associated with decreased use of alcohol (r = -.23) and 
marijuana (r = -.20; Simons & Gaher, 2005). The DTS has shown adequate test-retest reliability 
(r = .61; Simons & Gaher, 2005) in undergraduates and excellent internal consistency in the 
current study (α = .91). See Appendix F for the DTS. 
Marlowe-Crowne Social Desirability Scale – Short Form (M-C). The M-C short form 
(Reynolds, 1982) is an abbreviated version of the original 33-item scale (Crowne & Marlowe, 
1960). This 13-item true/false self-report questionnaire assesses social desirability, or the 
tendency to influence one’s scores by “faking good” or “faking bad” in order to present the way 
that is expected of the participant (Meehl & Hathaway, 1946). Lower scores represent less 
response bias, whereas higher scores represent greater social desirability. Previous studies 
investigating prescription opioid abuse have used the M-C as a measure of social desirability 
(e.g., Butler et al., 2007), and one found that individuals reporting less social desirability were 
typically men who reported craving their prescribed opioids (Wasan et al., 2009). In the current 
study, the M-C was used to examine social desirability, which may affect responding given the 
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sensitive questions on drug use. Consistent with its use in prior work, it would be expected that 
individuals in the non-drug use group would report higher social desirability, which would 
indicate potential inaccurate responding (Reynolds, 1982). The 13-item M-C has demonstrated 
excellent convergent validity with the original 33-item M-C (r = .93; Reynolds, 1982). 
Moreover, the 13-item short form has demonstrated adequate incremental validity (rKR-20 = .76) 
that is comparable to the original 33-item. However, in the current study, the M-C demonstrated 
poor reliability (α = .36), and results should be interpreted with caution. See Appendix G for the 
M-C. 
Nonmedical Prescription Drug Motives Questionnaire (NMPD-MQ). The NMPD-
MQ (Milner, 2015) is a 20-item self-report questionnaire assessing motives for using 
prescription drugs nonmedically. Items are rated on a 5-point Likert scale from 1 (“almost 
never/never”) to 5 (“almost always/always”). Items are adapted from the Modified Drinking 
Motives Questionnaire – Revised (DMQ-R; Cooper, 1994) and the Marijuana Motives Measure 
(Simons, Correia, Carey, & Borsari, 1998). The NMPD-MQ has four subscales determined by 
factor analysis: Self-medication (e.g., “to escape from your life”), social/recreation (e.g., 
“because it gives you a pleasant feeling”), performance (e.g., “to help focus”), and conformity 
(e.g., “so that others won’t kid you about not doing it”). In an unpublished dissertation, Milner 
(2015) demonstrated convergent validity, evidenced by positive correlations between the self-
medication subscale and the DMQ-R coping subscale, the social/recreation subscale and the 
DMQ-R enhancement subscale, the performance subscale and the DMQ-R social subscale, and 
the conformity subscale and the DMQ-R conformity subscale. In addition, this study 
demonstrated divergent validity for the NMPD-MQ as each subscale was negatively correlated 
with other dissimilar measures (e.g., self-medication was negatively related to positive affect and 
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sensation seeking). The NMPD-MQ demonstrated excellent internal consistency overall (α = .94) 
in the current sample of college students. See Appendix H for the NMPD-MQ. 
Use of Prescription Drugs Questionnaire. As there is no standardized measure to assess 
NMUPD broadly, this questionnaire was developed by the author to measure NMUPD. Items 
included: type of drug(s) used, type of use (i.e., using as prescribed or nonmedical use), 
frequency and quantity of use, and polysubstance drug use. The primary outcomes of interest 
include dichotomous reporting of past-year NMUPD (i.e., yes/no) and the frequency of NMUPD 
(i.e., “never” to “multiple times a day”). Additionally, all participants were asked to list the 
medication(s) used in the past year and indicate under which circumstances the medication was 
used within the respective classification (i.e., stimulants, sedatives, opioid painkillers). See 
Appendix I for the Use of Prescription Drugs Questionnaire. 
Sociodemographic Questionnaire and General Medical History. Participants reported 
their age, sex, race and ethnicity, year in school, current GPA, number of courses taken in the 
semester of their participation, major, and health insurance status. Also, participants reported 
substance use over the past year (i.e., alcohol, caffeine, tobacco, illicit drugs) and medical 
history, including items assessing lifetime occurrence of common medical problems, current or 
lifetime enrollment in therapy, and past-year prescribed and over-the-counter medications. See 
Appendix J for the Sociodemographic Questionnaire and General Medical History. 
Mirror Tracing Persistence Task – Computerized (MTPT-C). The MTPT-C (Strong 
et al., 2003) is a behavioral task designed to elicit psychological distress and to measure goal-
directed action in the context of distress. Participants are instructed to trace three increasingly 
difficult geometric shapes on a computer screen. Unbeknownst to the participant, the computer 
mouse is programmed to move in the opposite direction of its physical movement. When a 
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participant deviates from the line s/he is supposed to trace or stops moving the mouse for two 
seconds, a loud buzzer sounds and s/he is forced to begin the level again. Participants are given 
the option to quit at the fourth presentation of the geometric shape, which is the same level of 
difficulty as the previous shape (i.e., difficult). The first three rounds each last for one minute, 
while the fourth lasts up to seven minutes depending on when the participant quits the task. The 
primary outcome is latency to quit, which is measured in seconds.  
The MTPT-C has evidenced convergent validity in a depressed sample, such that 
depressed individuals terminate the task more quickly than non-depressed individuals (Ellis, 
Vanderlind, & Beevers, 2013). Further, there is evidence of predictive validity in that persistence 
on the MTPT-C can predict smoking cessation success, such that individuals who persist longer 
have more successful quit attempts (Steinberg et al., 2012). Behavioral measures of 
physiological and cognitive distress tolerance have been shown to be correlated with each other 
(McHugh et al., 2011; McHugh & Otto, 2011). However, the literature broadly indicates that 
behavioral measures of distress tolerance are poorly correlated with self-reported measures of 
distress tolerance. Indeed, both Glassman et al. (2016) and McHugh et al. (2011) found that the 
DTS and MTPT-C were not correlated (r = .05 and r = .07, respectively). This discrepancy 
suggests that there may be differences in the constructs assessed by the self-report and behavioral 
measures. Alternatively, the term “distress tolerance” may be multifaceted and comprise 
cognitive and physiological components of tolerating distress.  
Procedure 
Overview. The study protocol received approval from the University of Mississippi’s 
Institutional Review Board (IRB). All eligible participants were categorized in either the drug 
use or non-drug use group, and both groups completed a laboratory session including 
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questionnaires and the MTPT-C. Participants earned 1.0 hours of course credit for their 
participation.   
Recruitment. Students in psychology courses enrolled in the study via Sona Systems, an 
online study recruitment pool. An initial screening measure was included in the Sona screener to 
assess for past-year use of prescription drugs. Past-year use of prescription drugs was assessed 
rather than past-year nonmedical use due to the inclination of participants to provide inaccurate, 
yet socially desirable responses to these questions that may result in high rates of false negatives, 
as well as potential IRB concerns about confidentiality in the Sona screener and the illegal nature 
of NMUPD. Eligible participants were identified and invited via e-mail to sign up for the study, 
and those who reported using prescription drugs in the past year were encouraged to participate 
to ensure adequate power in the drug use group.  
Group Identification. Upon entering the lab, the informed consent process was reviewed 
with the participants by a trained research assistant. Written informed consent was obtained from 
interested individuals. First, participants completed the Use of Prescription Drugs Questionnaire 
(see Appendix I). Upon completion of the questionnaire, research assistants determined whether 
participants’ reported drug use met criteria for the drug use group or the non-drug use group. The 
drug use group was determined in accordance with the definition of NMUPD, which consisted of 
five items from the Use of Prescription Drugs Questionnaire. Participants who responded “yes” 
to using prescription medications 1) not prescribed to them, 2) taken beyond the amount they 
were told to take, and 3) for reasons other than how they were prescribed were assigned to the 
drug use group. Additionally, if participants reported using nonmedically or recreationally on at 
least one occasion within the past year or using more than the prescribed dosage (i.e., ≥ 1.5 times 
the prescribed dosage), they were classified in the drug use group. In the case of an individual 
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who initially reported no prescription drug use on the screener and then reported NMUPD in the 
lab, this individual was included in the drug use group. The non-drug use group was comprised 
of participants who reported no prescription drug use or abuse and/or reported medical use in the 
past year.  
Group assignment into the drug and non-drug use groups were checked by multiple 
investigators to ensure fidelity to the definition of NMUPD and to address anomalies, including 
unclear responding to NMUPD items. The study’s principal investigator and co-investigator 
discussed discrepancies in group assignment based on predetermined decision rules. Drug use 
information was kept separate from outcome data; therefore, all coders were blind to how the 
participant responded to key variables, thereby reducing potential bias when resolving 
discrepancies. See Appendix K for the group assignment flowchart.  
Laboratory Session Procedures. Participants completed a brief packet of online 
questionnaires via Qualtrics, including the AUDIT, ASI-3, CSSEC, DASS-21-Anxiety, DERS-
Impulse, DTS, M-C, NMPD-MQ, and the Sociodemographic Questionnaire and General Medical 
History (see Appendices A through H and J). Then participants participated in the MTPT-C 
(Strong et al., 2003). Upon completion of the laboratory session study procedures, participants 
received a debriefing describing the purpose of the study.  
In regard to the setting of the laboratory session, between one and ten participants 
completed the study at a time. A step was taken early in data collection to protect participants’ 
confidentiality, such that participants turned in the Use of Prescription Drugs Questionnaire in an 
manila envelope labeled “confidential.” Additionally, participants wore headphones or earphones 
during the MTPT-C in order to reduce ambient noise.  
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Data Analysis  
Power Analysis. Preliminary data collection suggested a medium between-groups effect 
size (Cohen’s d = .61) on the ASI-3. These data were used to conduct an a priori power analysis, 
which indicated that, for independent samples t-tests, a sample size of at least 86 participants, 43 
per group, was required to observe a medium between-group effect size using the parameters of a 
two-tailed test with alpha level of .05 and power of .80 (G*Power; Erdfelder, Faul, & Buchner, 
1996). Further, a review of the literature suggests that in order to achieve .80 power, a sample 
size of approximately 143 is needed to detect mediation (Fritz & MacKinnon, 2007).   
Data Cleaning Procedures. Statistical analyses were performed using SPSS Version 25 
(IBM Corp., 2017). Data were screened for accuracy errors, missing data, outliers, and 
assumptions. Of the 193 original participants, one participant was excluded for being outside of 
the appropriate age range, two participants were excluded for discrepant group assignment data, 
and six multivariate outliers were excluded using Mahalanobis distance. Data additionally met 
assumptions of multicollinearity, normality, linearity, homogeneity, and homoscedasticity. The 
final sample consisted of 184 participants, 115 in the non-drug use group and 69 in the drug use 
group. Between-group analyses were conducted to examine potential differences between the 
two groups that may have affected responses with regard to demographics and social desirability.  
Sample Characteristics. Type of misuse, frequency of use, and concurrent use of other 
substances were examined among the drug use group, and use of prescription drugs in general 
was examined among the full sample, including frequency of classes of prescription drugs used 
(i.e., stimulants, sedatives, and opioids), other prescribed medication (e.g., antidepressants), and 
alcohol and illicit drug use. 
 23 
 
Examination of Hypotheses 1 and 2. Point-biserial correlations were used to test 
associations between NMUPD and transdiagnostic variables (Hypothesis 1). Next, a series of 
independent samples t-tests were conducted to test Hypothesis 2 that compared to individuals 
without past-year NMUPD, individuals engaging in NMUPD would report significantly higher 
levels of anxiety, anxiety sensitivity, and emotion-driven impulse control difficulties, and 
significantly lower levels of distress tolerance, in addition to greater occurrence of stressful life 
events and greater diversity of substance use. Additional independent samples t-tests were 
utilized to examine group differences in alcohol use and polysubstance use (i.e., using another 
substance simultaneously with prescription drugs). Further, self-medication motives were not 
examined in the non-drug use group since this measure is only relevant to individuals who 
misuse prescription drugs. Therefore, Spearman correlations were used to assess the association 
between self-medication motives and frequency of prescription drug use, while a one sample t-
test was utilized to compare the self-medication motive mean of the current study to that of 
college-age prescription drug users from another study (Milner, 2015).  
Hypothesis 3 (Multiple Parallel Mediation). Multiple parallel mediation models were 
used to test Hypothesis 3, that anxiety would be associated with NMUPD via anxiety sensitivity, 
distress tolerance, and emotion-driven impulse control difficulties (see Figure 1). In multiple 
parallel mediation each mediator is simultaneously entered, which allows for each mediator to be 
examined while at the same time, accounting for shared variance between the other mediators. 
The PROCESS version 2.16 macro for SPSS was used to test the multiple mediation models 
(Hayes, 2013). PROCESS uses ordinary least squares regression with bootstrapping to estimate 
the indirect effects and to obtain confidence intervals for mediation models. Bias-corrected 
bootstrapping of 10,000 re-samples were used to calculate unstandardized beta (b) coefficients, 
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standard errors (SE), and 95% confidence intervals (95% CI) for all indirect (paths a1*b1, a2*b2, 
and a3*b3), direct (path c’), and total effects (path c). Confidence intervals that contain zero 
signify non-significant effects indicating that mediation is not present.  
Two parallel mediation models were tested to examine the relation of anxiety and 
NMUPD through various transdiagnostic mediators. The first model examined self-reported 
anxiety sensitivity, distress tolerance, and emotion-driven impulse control difficulties as 
mediators. The second model differed only in that behaviorally measured distress tolerance, 
rather than self-reported distress tolerance, was tested as a mediator. 
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RESULTS 
Participant Characteristics 
Chi-square goodness of fit and independent samples t-tests were used to test group 
differences in sex, age, and ethnicity, which indicated that there were no significant differences 
between groups (all p’s > .21). Social desirability was examined between the two groups as a 
potential confounding factor, and findings indicated that the drug use group reported more social 
desirability (M = 8.07, SD = 1.76) than the non-drug use group (M = 7.39, SD = 2.35; t (173.11) 
= -2.24, 95% CI [-1.28 – -0.08], p = .027).    
In total, 37.5% (n = 69) of the sample reported past-year NMUPD. Of these participants, 
34.8% reported misusing their own prescription by using more than the prescribed dose and 
29.0% used for reasons other than prescribed. Additionally, 59.4% reported using a medication 
that was not prescribed to them. With regard to NMUPD frequency, 29.0% reported doing so 
once, 27.5% reported monthly, 7.2% reported weekly, 5.8% reported 2 – 3 days a week, 14.5% 
reported daily, 2.9% reported multiple times a day, and 1.4% reported nonmedical use 
“randomly.” Lastly, 40.6% of the drug use group endorsed simultaneous polysubstance use, 
mixing prescription medication with other substances (i.e., primarily alcohol and marijuana).  
Among the total sample, 29.9% reported use of stimulants in the past year, which was 
primarily comprised of Adderall. In addition, 12.5% of the sample reported use of sedatives, 
including sleeping pills such as Trazodone and Ambien, and antianxiety medication such as 
Xanax and Klonopin. Lastly, 15.8% of the sample reported use of opioids, which primarily 
included hydrocodone. Notably, not all participants provided this information even if they did
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 report using prescription drugs. Furthermore, it is conceivable that college students may 
not know whether or not their use qualifies as abuse, and further, they may not know the exact 
medication and dose that they are using. Of the total sample, 10.3% reported past-year use of 
other prescribed medications, including antidepressants (i.e., citalopram), headache medication 
(i.e., Topamax), and over-the-counter pain relievers (e.g., naproxen). Regarding alcohol use, 
9.2% of the sample scored in a range indicative of potential alcohol abuse, which is considerably 
lower than a nationally representative sample of undergraduate students (i.e., 31.6%; Knight et 
al., 2002). Indeed, the median frequency of past-year alcohol use was “less than monthly,” 
indicating that half of the sample reported never using alcohol in the past year, and half reported 
using monthly or weekly. Additionally, 16.1% of the entire sample reported past-year illicit drug 
use, including marijuana (16.5%), cocaine (2.3%), and hallucinogens (0.6%). 
Regarding psychological characteristics, the overall sample endorsed a low level of 
anxiety (M = 1.89, SD = 3.34) which fell in the normal range, a subclinical level of anxiety 
sensitivity (M = 15.97, SD = 4.90), and a “severe” level with regard to stressful events 
experienced (M = 410.44, SD = 182.19). Further, scores on the DERS-Impulse (M = 11.77, SD = 
5.10) and DTS (M = 48.66, SD = 12.50) were consistent with other studies using these measures 
with college-age participants (respectively, Gratz & Roemer, 2004; Anestis, Selby, Fink, & 
Joiner, 2007). The sample, on average, did not report a hazardous level of drinking, and reported 
very little illicit drug use outside of NMUPD. 
Test of Study Hypotheses 
Zero-order Correlations and Group Differences. See Table 1 for zero-order 
correlations and descriptive statistics among primary variables. The first hypothesis was not 
supported, such that NMUPD was not significantly associated with any of the transdiagnostic 
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variables (all p’s > .05). As expected, the transdiagnostic variables were significantly associated 
with one another (all p’s < .001), and NMUPD was associated with both alcohol use (rpb = .401, 
p, < .001) and illicit drug use (rpb = .373, p, < .001). Consistent with previous studies, self-
reported and behaviorally measured distress tolerance were not significantly correlated with one 
another (r = .060, p > .05). Contrary to the second hypothesis, none of the transdiagnostic 
variables were significantly different between the drug and non-drug use groups, nor were 
occurrence of stressful events (see Table 2).  
Diversity of drug type was significantly different between the two groups, such that 
individuals who engaged in past year NMUPD reported more diversity of drug use (M = 2.14, 
SD = 1.67), including illicit drugs and alcohol, than individuals who reported medical or no use 
(M = 0.71, SD = 0.97). Additionally, there was a significant difference between individuals who 
abused prescription drugs and those who did not in alcohol use and polysubstance use behaviors. 
Specifically, those engaging in NMUPD reported more alcohol (M = 4.17, SD = 3.55) and 
polysubstance use (M = 0.41, SD = 0.50) than the non-drug use group (Malc = 1.57, SDalc = 2.44; 
Mpoly = 0.04, SDpoly = 0.21; see Table 2). Lastly, self-medication motives for prescription drug 
use was significantly associated with NMUPD frequency (ρ = .252, p = .037), and was 
significantly higher than a large sample of undergraduate students who reported lifetime 
prescription drug use, (t (68) = 12.89, 95% CI [6.04 – 8.26], p < .001). Specifically, the current 
sample reported a mean of 9.02 (SD = 4.61) compared to the validation mean of 1.86 (SD = 
1.05).  
Multiple Parallel Mediation. Regarding the third hypothesis, the first parallel mediation 
model analyses revealed that the a1, b1, and c1 paths were significant (see Figure 2 for the results 
of each path of the first model). However, the indirect paths from anxiety to NMUPD through 
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anxiety sensitivity (b = -0.0184, SE = 0.0362, 95% CI [-0.0893 – 0.0525]), distress tolerance (b = 
-0.0086, SE = 0.0162, 95% CI [-0.0403 – 0.0230]), and emotion-driven impulse control 
difficulties (b = 0.0302, SE = 0.0403, 95% CI [-0.0487 – 0.1091]) were not significant, 
indicating no evidence of mediation. Similarly, the second model examining behavioral distress 
tolerance indicated significant b1 and c1 paths, but a nonsignificant a1 path (see Figure 3 for the 
result of each path of the second model). Further, the model yielded a nonsignificant indirect 
effect from anxiety to NMUPD through anxiety sensitivity (b = -0.0158, SE = 0.0346, 95% CI [-
0.0835 – 0.0520]), distress tolerance (b = -0.0006, SE = 0.0020, 95% CI [-0.0045 – 0.0034]), and 
emotion-driven impulse control difficulties (b = 0.0497, SE = 0.0373, 95% CI [-0.0234 – 
0.1228]), indicating no evidence of mediation.1  
 
                                                 
1 Single mediation models examining each mediator variable independently were also examined and yielded the 
same pattern of null findings. 
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DISCUSSION 
Rates of nonmedical use of prescription drugs (NMUPD) have increased across all age 
groups, but are especially high among young adults (Blanco et al., 2007). As such, the current 
study aimed to further the understanding of NMUPD in college students by examining risk 
factors that are known to contribute to both substance use and anxiety. The findings bring to light 
the seriousness of the nonmedical use of prescription drugs, and particularly, the high frequency 
in which it occurs in college students as well as concurrent use with other substances. In this 
sample, nearly 40% reported past-year NMUPD, which is considerably higher than national 
averages (15%; SAMHSA, 2015). Although it is possible that the rate of NMUPD in this sample 
is uncharacteristically high due to the targeted recruitment of individuals who reported use of 
prescription drugs, this finding is not unprecedented as another study found that the rate of 
NMUPD among undergraduates in the past three months was 48% (Holloway & Bennett, 2012).   
Consistent with literature (e.g., Huang et al., 2006), the most frequently endorsed class of 
prescription drug was stimulants, which was about twice as high as the next most frequent class, 
opioids, with sedatives being the least commonly used medication. The majority of participants 
who engaged in NMUPD did so by using medications that were not prescribed to them, while a 
smaller portion misused their own prescription medication. Similarly, prior work found that 
approximately one-third of university students have reported using prescription drugs that are not 
their own, while 23% reported misusing their own prescription and 11% sold, traded, or gave 
away their prescribed medication (Holloway & Bennett, 2012). Of students who reported 
NMUPD in the current sample, 40% endorsed simultaneous polysubstance use.  
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This rate closely reflects large samples of undergraduates who used prescription drugs 
and alcohol simultaneously (56.8%; McCabe, Cranford, Morales, & Young, 2006).  
In the current study, point-biserial correlations were examined among past-year NMUPD 
and relevant transdiagnostic vulnerability factors (i.e., anxiety sensitivity, distress tolerance, 
emotion-driven impulse control difficulties). Contrary to our first hypothesis, these 
transdiagnostic variables were not significantly associated with NMUPD. However, past-year 
use of NMUPD was associated with all substance use variables, including alcohol use and use of 
illicit drugs. Interestingly, counter to prior work, alcohol and illicit drug use were similarly not 
correlated with the transdiagnostic variables (Simons & Gaher, 2005; Simons, Gaher, Correia, 
Hansen, & Christopher, 2005).  
The second hypothesis examined differences among individuals who reported past-year 
NMUPD and those who reported medical use or no use. Specifically, we examined group 
differences among trait anxiety, anxiety sensitivity, distress tolerance, and emotion-driven 
impulse control difficulties, as well as the presence of stressful events, diversity of substance use, 
and how NMUPD relates to self-medication motives. Contrary to the hypothesis, there were no 
significant differences between individuals who engaged in past-year NMUPD and those who 
did not on anxiety, the three transdiagnostic vulnerabilities, or occurrence of stressful events. 
However, the finding that alcohol and illicit drug use is more than doubled among prescription 
drug abusers compared to nonusers is consistent with literature that suggests that likelihood of 
alcohol and illicit drug use disorders is increased for individuals reporting lifetime NMUPD 
(Huang et al., 2006). Additionally, correlational findings and mean comparison to a similar 
sample (Milner, 2015) suggest that students may engage in NMUPD as a self-medication 
strategy. 
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Findings suggest that students reporting past-year NMUPD are more likely to engage in 
heavier alcohol consumption and simultaneous polysubstance use than their abstinent 
counterparts. Further, over half of students reporting NMUPD also reported simultaneous 
polysubstance use, most prominently alcohol. Despite the overall low rates of alcohol and illicit 
drug use in the current study compared to representative samples, the results suggest that 
NMUPD is associated with substance use generally, and in particular, with higher rates of 
alcohol, illicit drug, and simultaneous polysubstance use. This high rate and the increased rate of 
alcohol use in the NMUPD group is particularly alarming given that prescription drugs with 
sedative qualities (e.g., benzodiazepines, opioid painkillers) augment the depressogenic effects of 
alcohol, which can to lead to reduced respiratory function or failure and potentially overdose 
and/or death (White & Irvine, 1999).  
Although we would expect anxiety to be on a continuum, trait anxiety lacked variability 
in the current study, such that the mean level anxiety was very low (see Osman et al., 2012; 
Table 2), with 63.6% of the sample reporting no anxiety (0 out of possible 21). As such, it is 
conceivable that prescription drugs, or substances in general, were not used to cope with 
problematic anxiety, as the sample, on average, did not experience problematic anxiety. Lastly, 
both prescription drug abusers and nonusers fell within the “severe stress” category regarding 
occurrence of stressful events, which reflects the literature stating that college is a time of 
increased stress (Misra & Castillo, 2004; Misra, McKean, West, & Russo, 2000), and could be 
an explanation as to why there was not a significant difference in occurrence of stressful events. 
Additionally, this measure rank orders stressful events from most (i.e., death of a close family 
member) to least stressful (i.e., minor traffic violations). Potentially, students experienced similar 
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events at roughly equal rates (e.g., “first semester in college,” “problems with a girlfriend or 
boyfriend”), which may have resulted in scores being equivalent between the two groups.  
 The third hypothesis tested anxiety sensitivity, distress tolerance (both self-report and 
behavioral), and emotion-driven impulse control difficulties as parallel mediators of the relation 
of anxiety and NMUPD. Contrary to expectations, none of the transdiagnostic variables mediated 
the relationship. However, the sample may be limited in that there is limited variance in the 
outcome variable, and NMUPD was measured dichotomously rather than continuously. 
Moreover, it may be difficult for the hypothesized mechanisms (i.e., transdiagnostic 
vulnerabilities) to account for problematic substance use given the very low level of trait anxiety 
exhibited in the sample. That is, individuals with normative levels of anxiety would not 
necessarily engage in the posited negative reinforcement cycle for substance abuse (i.e., 
NMUPD). Alternatively, it is possible that these constructs simply do not serve as mediators to 
the relation of anxiety and NMUPD in this sample.  
It is unclear why none of the primary study variables or substance use variables were 
associated with one another, but there are several possible explanations. First, this may indicate 
that the current sample of college students is atypical compared to those reported in extant 
literature in regard to substance use rates. Indeed, alcohol use in this sample was markedly lower 
than the national average for college students (9.2% in the current sample compared to 31.6%; 
Knight et al., 2002). Similarly, the rate of past-year marijuana use among college students in a 
large, representative survey was higher than in the current study (30% compared to 16.5%, 
respectively; Mohler-Kuo, Lee, & Wechsler, 2003). Considering that this sample is, on average, 
on the low end of emerging adulthood, it is possible that they may behave more like high school 
students than college students. However, a sample of high school students who reported drinking 
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alcohol in the past 30 days evidenced higher rates (44.9%; Miller, Naimi, Brewer, & Jones, 
2007) than in the current sample of college students. Alternatively, the setting of the current 
study, which ran up to 10 participants at a given time, may have contributed to potential sample 
bias due to perceived lack of anonymity.  
Limitations  
Within the current study, several limitations warrant consideration. A potential chief 
limitation is the way in which NMUPD was operationally defined as it may have limited 
generalizability of the results to the overall population of undergraduate students who engage in 
NMUPD. In the current study, a broad definition of NMUPD was used to capture all behaviors 
that are associated with misuse of prescription drugs and is consistent with definitions provided 
by both NIDA and SAMHSA. Specifically, NMUPD was defined as using prescription 
medication “from a source other than your own prescription, beyond the amount you were told to 
take, or for some reason other than prescribed,” and examples were provided to orient 
participants (i.e., “some of the common ways include taking stimulants to stay up at night, taking 
Xanax to feel good, or taking a leftover pain pill for an ache that it was not specifically 
prescribed for”). This definition is consistent with literature that describes misuse of medication 
that was prescribed to the individual, using medication from any source other than a provider, 
and using for a nonmedical or recreational purpose (see Holloway & Bennett, 2012; Kelly et al., 
2015). In contrast, other studies simply defined NMUPD as use of a prescribed medication 
without a doctor’s prescription or medication that was not prescribed to them (Jeffers et al., 
2015; McCabe et al., 2005). Rates of past-year misuse are much lower in studies using this 
definition (e.g., less than 30%; Jeffers et al., 2015).  
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Although the measure used in this study, the Use of Prescription Drugs Questionnaire, 
was based on existing definitions and research, it is not validated, and the items may have been 
unclear to some participants. For instance, participants may have misunderstood items such as 
frequency of prescription drug use, which was designed to be responded to only for participants 
who engaged in past-year NMUPD. It may be that some participants responded to this item 
regardless of nonmedical use, which might explain why the frequency of daily NMUPD is so 
high (e.g., participants who are prescribed amphetamines for attention difficulties would take 
them daily). Given this limitation, this measure may lack internal validity as participants may 
have inconsistently responded to items on this questionnaire, which consequently limited 
variability among items. As such, these results may not extend to the broader population of 
students engaging in NMUPD.   
A related limitation concerns the characteristics of the individuals reporting NMUPD. 
Alcohol use rates were lower in the current study than observed in previous studies of college 
students and high schoolers; therefore, the correlational and descriptive findings suggest that the 
sample characteristics in regard to substance use may not generalize to other college-age 
samples. Relatedly, the perceived anonymity in the current study may have been an issue in the 
reporting of illegal activity (e.g., NMUPD, underage drinking). However, this could also point to 
the complexity of prescription drug use and abuse, especially considering that the drug use group 
was quite heterogeneous. For example, there was considerable variability in frequency of 
NMUPD, with 29.0% of the drug use group reporting past-year NMUPD on only one occasion, 
27.5% reporting monthly, and 7.2% reporting weekly. There is reason to believe that an 
individual abusing prescription drugs once in the past year would be characteristically different 
regarding anxiety and substance use than someone reporting weekly NMUPD. Additionally, the 
 35 
 
current study did not examine different classes of prescription drug abuse, but instead examined 
NMUPD overall. There could be important distinctions among individuals who use stimulants, 
sedatives, opioids, or a combination of the three classes. Cumulatively, these findings suggest the 
importance of examining NMUPD functionally.  
An additional limitation is that the sample may lack heterogeneity regarding 
sociodemographic variables, specifically that the sample is mostly freshmen (71.2%), female 
(75.5%), and White (71.7%). As NMUPD has been associated with older students and males 
(McCabe et al., 2005), the sample may limit the generalizability of current findings. However, 
the extant literature is mixed concerning sex as a risk factor (e.g., Young et al., 2012), as some 
studies have found that the likelihood of NMUPD has been shown to be higher in men (Huang et 
al., 2006; Lanier & Farley, 2011), others among women (Simoni-Wastila, 2000), and some 
finding no significant difference between the sexes (Simoni-Wastila, Ritter, & Strickler, 2004). 
Lastly, the study sample was collected from a large, southeastern public institution located in a 
rural area; however, NMUPD may differ in other regions of the country or urban areas. Indeed, 
McCabe and colleagues (2005) report that universities in the northeastern region of the United 
States and those that have competitive admission criteria encounter higher rates of past-year and 
past-month nonmedical stimulant use than other regions of the country and less competitive 
admission criteria, respectively.  
In addition to the aforementioned methodological and sample characteristic issues, the 
primary study variables (i.e., NMUPD and transdiagnostic variables), with the exception of the 
MTPT-C, were retrospective self-reports. Further, the overall low rate of trait anxiety observed 
in this study and the poor reliability evidenced by the ASI-3 are limitations of the methodology 
that should be examined in future work. Lastly, given the sensitive nature of illegal drug use, it 
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may be possible that students were dishonest in reporting their drug use. To address this concern, 
participant materials were kept in folders that were marked as “confidential” and were told that 
their results would be entirely anonymous.  
Future Directions and Conclusions. Overall, the results of the current study contribute 
to the growing body of literature supporting the adverse outcomes associated with prescription 
drug abuse, and underscore the need for future studies to hypothesize intervention efforts to 
address these alarming findings. Such efforts should include a thorough screener for 
polysubstance use among college students given the high rates of substance abuse in this 
population. Specifically, it may be beneficial to administer screeners to students who report any 
substance use, as rates of NMUPD in the current study and extant literature are higher among 
students engaging in other substance use. In particular, simultaneous polysubstance use was 
higher among students engaging in past-year NMUPD, suggesting this population may be at 
increased risk for risky substance use behaviors compared to students who do not abuse 
prescription drugs.  
Regarding future research endeavors, the null findings and methodological limitations of 
the current study highlight key areas for consideration in future studies. An important next 
direction would be examining the role of the transdiagnostic factors as mechanisms in the 
relation of anxiety and NMUPD in an anxious sample. Certainly, results would be strengthened 
if anxiety and NMUPD were assessed via clinical interview to determine whether symptoms 
reach clinical significance, or other non-retrospective method such as ecological momentary 
assessment to measure substance use behaviors and emotional experiences presently. Additional 
studies should consider use of such methodology for making inferences to individuals with 
anxiety symptoms that reach clinical significance, and to better assess NMUPD severity and 
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impairment. If using self-report, future studies would benefit from a validated measure of 
NMUPD that is not exclusive to one class of prescribed medication, and should consider rates in 
the context of the definition of NMUPD that is being used. In addition, independent examination 
of various classes of prescription drugs is warranted in order to identify unique characteristics 
associated with a particular class of prescribed medication. Given the sensitive nature of illegal 
prescription drug use, future studies would benefit from increasing the appearance of anonymity, 
potentially by placing screen dividers between participants. Lastly, use of a larger, longitudinal 
sample is warranted to determine temporal and causal conclusions regarding anxiety and 
NMUPD.   
The current study expands on the extant literature regarding correlates of past-year 
NMUPD in college students, an at risk population. As rates of NMUPD are increasing among 
college students, it is important to understand risk factors and risky behavior that are associated 
with prescription drug abuse. Although the results of the current study do not indicate that 
anxiety is a risk factor for past-year NMUPD in college students, they do suggest that 
prescription drug abusers engage in higher rates of risky behavior including other substance 
abuse and simultaneous polysubstance use. As such, future studies are called upon to further 
examine the risk factors and associated risky behaviors associated with NMUPD among college 
students. 
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APPENDIX A: THE ALCOHOL USE DISORDERS IDENTIFICATION TEST 
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Select the appropriate answer. 
1. How often do you have a drink 
containing alcohol?  
(0) Never (Skip to Questions 9-10) 
(1) Monthly or less 
(2) 2 to 4 times a month 
(3) 2 to 3 times a week 
(4) 4 or more times a week 
 
2. How many drinks containing alcohol 
do you have on a typical day when 
you are drinking? 
(0) 1 or 2 
(1) 3 or 4 
(2) 5 or 6 
(3) 7, 8, or 9 
(4) 10 or more 
 
3. How often do you have six or more 
drinks on one occasion?  
(0) Never 
(1) Less than monthly 
(2) Monthly 
(3) Weekly 
(4) Daily or almost daily 
 
4. How often during the last year have 
you found that you were not able to 
stop drinking once you had started? 
(0) Never 
(1) Less than monthly 
(2) Monthly 
(3) Weekly 
(4) Daily or almost daily 
 
5. How often during the last year have 
you failed to do what was normally 
expected from you because of 
drinking?  
(0) Never 
(1) Less than monthly 
(2) Monthly 
(3) Weekly 
(4) Daily or almost daily 
 
6. How often during the last year have 
you been unable to remember what 
happened the night before because 
you had been drinking?  
(0) Never 
(1) Less than monthly 
(2) Monthly 
(3) Weekly 
(4) Daily or almost daily 
 
7. How often during the last year have 
you needed an alcoholic drink first 
thing in the morning to get yourself 
going after a night of heavy 
drinking?  
(0) Never 
(1) Less than monthly 
(2) Monthly 
(3) Weekly 
(4) Daily or almost daily 
 
8. How often during the last year have 
you had a feeling of guilt or remorse 
after drinking?  
(0) Never 
(1) Less than monthly 
(2) Monthly 
(3) Weekly 
(4) Daily or almost daily 
 
9. Have you or someone else been 
injured as a result of your drinking?  
(0) No 
(2) Yes, but not in the last year 
(4) Yes, during the last year 
 
10. Has a relative, friend, doctor, or 
another health professional 
expressed concern about your 
drinking or suggested you cut down?  
(0) No 
(2) Yes, but not in the last year 
(4) Yes, during the last year 
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APPENDIX B: ANXIETY SENSITIVITY INDEX – 3 
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Please circle the number that best corresponds to how much you agree with each item. If any 
items concern something that you have never experienced (e.g., fainting in public) answer on the 
basis of how you think you might feel if you had such an experience. Otherwise, answer all items 
on the basis of your own experience. Be careful to circle only one number for each item and 
please answer all items. 
 Very 
little 
A 
little 
Some Much 
Very 
much 
1. It is important for me not to appear nervous. 0 1 2 3 4 
2. When I cannot keep my mind on a task, I 
worry that I might be going crazy. 
0 1 2 3 4 
3. It scares me when my heart beats rapidly. 0 1 2 3 4 
4. When my stomach is upset, I worry that I 
might be seriously ill.  
0 1 2 3 4 
5. It scares me when I am unable to keep my 
mind on a task. 
0 1 2 3 4 
6. When I tremble in the presence of others, I 
fear what people might think of me.  
0 1 2 3 4 
7. When my chest feels tight, I get scared that I 
won’t be able to breathe properly.  
0 1 2 3 4 
8. When I feel pain in my chest, I worry that I 
am going to have a heart attack.  
0 1 2 3 4 
9. I worry that other people will notice my 
anxiety.  
0 1 2 3 4 
10. When I feel “spacey” or spaced out I worry 
that I may be mentally ill.  
0 1 2 3 4 
11. It scares me when I blush in front of people.  0 1 2 3 4 
12. When I notice my heart skipping a beat, I 
worry that there is something seriously wrong 
with me.  
0 1 2 3. 4 
13. When I begin to sweat in a social situation, I 
fear people will think negatively of me.  
0 1 2 3 4 
14. When my thoughts seem to speed up, I worry 
that I might be going crazy.  
0 1 2 3 4 
15. When my throat feels tight, I worry that I 
could choke to death.  
0 1 2 3 4 
16. When I have trouble thinking clearly, I worry 
that there is something wrong with me.  
0 1 2 3 4 
17. I think it would be horrible for me to faint in 
public. 
0 1 2 3 4 
18. When my mind goes blank, I worry there is 
something terribly wrong with me.  
0 1 2 3 4 
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Rank: Value: Happened: Score: Life Event: 
1 100   Death of a close family member 
2 73   Death of a close friend 
3 65   Divorce between parents 
4 63   Serious legal problems 
5 63   Major personal injury or illness 
6 58   Responsibilities for others, such 
as children/spouse 
7 50   Threat to major source of 
income 
8 47   Difficulty with roommate(s) 
9 45   Change in health of a family 
member 
10 45   Pregnancy 
11 44   Sexual problems 
12 40   Serious disagreements with 
parents 
13 39   Change in lifestyle for financial 
reasons  
14 39   Difficulty in identifying a major 
15 39   Serious argument with close 
family member 
16 39   Problems with a girlfriend or 
boyfriend 
17 37   Having to repeat a course 
18 37   Increased workload at school 
19 36   Outstanding personal 
achievement  
20 35   First semester in college 
21 31   Change in living conditions 
22 30   Serious disagreements with an 
instructor 
23 29   Lower grades than expected 
24 29   Change in sleeping habits 
25 29   Change in social habits 
26 28   Change in eating habits 
27 26   Chronic car problems 
28 26   Change in number of family get 
togethers 
29 25   Too many missed classes 
30 24   Change in plans for a major 
31 23   Dropped more than one class 
32 20   Minor traffic violations 
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APPENDIX D: DEPRESSION ANXIETY STRESS SCALE – 21 – ANXIETY  
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INSTRUCTIONS: Please read each statement and choose the number which indicates how 
much the statement applied to you over the past week. There are no right or wrong answers.  
Do not spend too much time on any statement. The rating scale is as follows:  
 
0 = Did not apply to me at all 
1 = Applied to me some degree, or some of the time 
2 = Applied to me a considerable degree, or a good part of the time  
3 = Applied to me very much, or most of the time 
  
 
Did not 
apply to 
me 
Applied to 
me some 
degree, or 
some of 
the time 
 
Applied to 
me a 
considerable 
degree, or a 
good part of 
the time 
Applied to me 
very much, or 
most of the 
time 
 
1. I was aware of dryness in my 
mouth. 0 1 2 3 
2.  I experience breathing 
difficulty (e.g., excessively rapid 
breathing, breathlessness in the 
absence of physical exertion). 
0 1 2 3 
3. I experienced trembling (e.g., 
in the hands). 0 1 2 3 
4. I was worried about situations 
in which I might panic and make 
a fool of myself. 
0 1 2 3 
5. I felt I was close to panic. 
0 1 2 3 
6. I was aware of the action of 
my heart in the absence of 
physical exertion (e.g., sense of 
heart rate increase, heart missing 
a beat). 
0 1 2 3 
7. I felt scared without any good 
reason. 0 1 2 3 
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APPENDIX E: DIFFICULTIES IN EMOTION REGULATION SCALE – IMPULSE 
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Please indicate how often the following statements apply to you by filling in the appropriate 
numbered bubble from the scale below: 
1=almost never (0-10%); 2=sometimes (11-35%); 3=about half the time (36-65%); 4=most of 
the time (66-90%); 5=almost always (91-100%). 
 Almost 
never 
Sometimes 
About half 
the time 
Most of the 
time 
Almost 
always 
1. I experience my 
emotions as 
overwhelming and 
out of control. 
1 2 3 4 5 
2.  When I’m 
upset, I become 
out of control. 
1 2 3 4 5 
3. When I’m upset, 
I feel out of 
control. 
1 2 3 4 5 
4. When I’m upset, 
I feel like I can 
remain in control 
of my behaviors. 
1 2 3 4 5 
5. When I’m upset, 
I have difficulty 
controlling my 
behaviors. 
1 2 3 4 5 
6. When I’m upset, 
I lose control over 
my behaviors. 
1 2 3 4 5 
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APPENDIX F: DISTRESS TOLERANCE SCALE 
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Directions: Think of times that you feel distress or upset. Select the item that best describes your 
beliefs about feeling distressed or upset.  
 
 
Strongly 
Agree 
Mildly 
Agree 
Agree 
and 
Disagree 
Equally 
Mildly 
Disagree 
Strongly 
Disagree 
1. Feeling distressed or upset is 
unbearable to me. 
1 2 3 4 5 
2. When I feel distress or upset, all I 
can think about is how bad I feel. 
1 2 3 4 5 
3. I can’t handle feeling distressed or 
upset. 
1 2 3 4 5 
4. My feelings of distress are so intense 
that they completely take over. 
1 2 3 4 5 
5. There’s nothing worse than feeling 
distressed or upset. 
1 2 3 4 5 
6. I can tolerate being distressed or 
upset as well as most people. 
1 2 3 4 5 
7. My feelings of distress or being 
upset are not acceptable. 
1 2 3 4 5 
8. I’ll do anything to avoid feeling 
distressed or upset.  
1 2 3 4 5 
9. Other people seem to be able to 
tolerate feeling distress or upset 
better than I can. 
1 2 3 4 5 
10. Being distressed or upset is always 
a major ordeal for me. 
1 2 3 4 5 
11. I am ashamed of myself when I feel 
distressed or upset. 
1 2 3 4 5 
12. My feelings of distress or being 
upset scare me. 
1 2 3 4 5 
13. I’ll do anything to stop feeling 
distressed or upset. 
1 2 3 4 5 
14. When I feel distressed or upset, I 
must do something about it 
immediately. 
1 2 3 4 5 
15. When I feel distressed or upset, I 
cannot help but concentrate on how 
bad the distress actually feels.  
1 2 3 4 5 
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APPENDIX G: MARLOWE-CROWNE SOCIAL DESIRABILITY SCALE – SHORT FORM  
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Instructions: Listed below are a number of statements concerning personal attitudes and traits. 
Read each item and decide whether the statement is true or false as it pertains to you. 
 
 
1. It is sometimes hard for me to go on with my work if I am not encouraged.  
True False 
2. I sometimes feel resentful when I don’t get my own way. True False 
3. On a few occasions, I have given up doing something because I thought too 
little of my ability.  True False 
4. There have been times when I felt like rebelling against people in authority 
even though I knew they were right. True False 
5. No matter who I’m talking to, I’m always a good listener.  True False 
6. There have been occasions when I took advantage of someone.  True False 
7. I’m always willing to admit it when I make a mistake.  True False 
8. I sometimes try to get even, rather than forgive and forget.  True False 
9. I am always courteous, even to people who are disagreeable.  True False 
10. I have never been irked when people expressed ideas very different from 
my own. 
True False 
11. There have been times when I was quite jealous of the good fortune of 
others. 
True False 
12. I am sometimes irritated by people who ask favors of me. True False 
13. I have never deliberately said something that hurt someone’s feelings.  True False 
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APPENDIX H: NONMEDICAL PRESCRIPTION DRUG MOTIVES QUESTIONNAIRE 
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Below is a list of reasons people sometimes give for nonmedical prescription drug use. Think 
about all of the times that you have used prescription drugs nonmedically and indicate how often 
you have done so for each of the below reasons. 
 
Almost 
Never/Never 
Some of the 
Time 
Half of the 
Time 
Most of 
the Time 
Almost 
Always/
Always 
1. Because your 
friends pressure you 
to use them 
1 2 3 4 5 
2. Because it helps 
you when you feel 
depressed or nervous 
1 2 3 4 5 
3. To be sociable 1 2 3 4 5 
4. So that others 
won’t kid you about 
not doing it 
1 2 3 4 5 
5. To get high 1 2 3 4 5 
6. Because it gives 
you a pleasant feeling 
1 2 3 4 5 
7. Because it 
improves parties and 
celebrations 
1 2 3 4 5 
8. To forget about 
your problems 
1 2 3 4 5 
9. Because it’s fun 1 2 3 4 5 
10. To be liked 1 2 3 4 5 
11. To manage pain 1 2 3 4 5 
12. To be more 
efficient 
1 2 3 4 5 
13. To escape from 
your life 
1 2 3 4 5 
14. To help you stay 
organized 
1 2 3 4 5 
15. To perform better 
on school work or on 
tests 
1 2 3 4 5 
16. Because it helps 
to increase your 
alertness 
1 2 3 4 5 
17. To help you sleep 1 2 3 4 5 
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18. To help focus 1 2 3 4 5 
19. Because you 
didn’t want to be the 
only one not doing it 
1 2 3 4 5 
20. Because it 
counteracts the 
effects of other drugs 
1 2 3 4 5 
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APPENDIX I: USE OF PRESCRIPTION DRUGS QUESTIONNAIRE 
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Doctors sometimes prescribe medicine to calm people down or to help them relax their muscles, 
to help people sleep, deal with pain, or lose weight. Besides the medical uses, people sometimes 
take these pills on their own without the direction of a doctor or recreationally. This is 
sometimes called “nonmedically,” which means from a source other than your own prescription, 
beyond the amount you were told to take, or some reason other than prescribed. For instance, 
some of the common nonmedical or recreational uses include taking stimulants to stay up at 
night, taking Xanax to feel good, or taking a leftover pain pill for an ache that it was not 
specifically prescribed for.  
 
Instructions: Please answer the following questions pertaining to past year prescription drug 
use.  
 
1. Check the boxes of any medication(s) you use, either prescribed or non-prescribed. 
 Stimulants (e.g., amphetamines: Adderall [speed]; Ritalin [Vitamin R], Vyvanse, 
“bennies,” “uppers”) 
o Type (if known): 
_______________________________________________________________ 
 Sedatives (e.g., anxiolytics: Ativan, Klonopin, Valium, Xanax [bars], “barbs,” 
“benzos,” “downers,” “tranks;” sleeping pills: Ambien 
o Type (if known): 
_______________________________________________________________ 
 Opioid painkillers (e.g., Codeine [cody, Purple Drank], Hydrocodone/Lortab/Vicodin 
[hydro, norco, tabs, vike], Oxycodone/OxyContin/Percocet [oxy, percs]) 
o Type: (if known): 
_______________________________________________________________ 
 Other
_____________________________________________________________________ 
2. Have you used prescription stimulants, sedatives, opioid painkillers, or any other prescription 
medications that were not prescribed to you?      YES  NO 
 
3. Have you used prescription stimulants, sedatives, opioid painkillers, or any other prescription 
medications beyond the amount you were told to take (either in a day or in one dose)?  
YES  NO 
 
4. Have you used prescription stimulants, sedatives, opioid painkillers, or any other prescription 
medications for reasons other than prescribed?       YES  NO 
 
5. If yes to any of the above, what 
medication(s)?
______________________________________________________________________________ 
 
5a. In what circumstances do you use stimulants? 
 Social (e.g., partying or pregaming, enhancement of good mood) 
 Academic (e.g., to stay up later, enhance studying) 
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 Coping (e.g., to relieve stress or anxiety, reduce bad mood) 
 Other
_____________________________________________________________________ 
 None 
5b. In what circumstances do you use sedatives? 
 Social (e.g., partying or pregaming, enhancement of good mood) 
 Academic (e.g., to stay up later, enhance studying) 
 Coping (e.g., to relieve stress or anxiety, reduce bad mood) 
 Other
_____________________________________________________________________ 
 None 
5c. In what circumstances do you use opioid painkillers? 
 Social (e.g., partying or pregaming, enhancement of good mood) 
 Academic (e.g., to stay up later, enhance studying) 
 Coping (e.g., to relieve stress or anxiety, reduce bad mood) 
 Other
_____________________________________________________________________ 
 None 
6. In the past 12 months, how much have you used prescription medications recreationally or 
nonmedically?  
 
0 
Never 
1 
Once 
2 
Monthly 
3 
Weekly 
4 
2-3 days 
per week 
5 
Daily 
6 
Multiple 
times a 
day 
Other: 
 
Dose can mean both the dosage prescribed (i.e., the amount in milligrams) and the frequency 
taken (i.e., amount of times used per day, week, etc.). Refer to the medication information sheet 
for standard dosages. 
 
7.  When you are using prescription drugs, how much, on average, do you take?  
1 
Less than 
½ the 
prescribed 
dosage 
2 
½ of the 
prescribed 
dosage 
3 
Prescribed 
dosage 
4 
1.5 times the 
prescribed 
dosage 
5 
Twice the 
prescribed 
dosage 
6 
More than 
twice the 
prescribed 
dosage 
8. Do you ever use prescription drugs simultaneously with any other substance including 
alcohol, marijuana, other prescription drugs, or any other illicit drugs?   
           YES  NO 
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8a. If so, which substance(s)? 
________________________________________________________________________ 
 
 
9. Over the past year, has your use of prescription drugs been associated with feeling a strong 
desire or urge to use?         YES NO 
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APPENDIX J: SOCIODEMOGRAPHIC QUESTIONNAIRE AND GENERAL MEDICAL 
HISTORY 
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1. Sex 
a. Male 
b. Female 
c. Transgender 
 
2. Age _____________ 
 
3. Date of birth _____________ 
 
4. Ethnicity 
a. Not Hispanic or Latino 
b. Hispanic or Latino 
 
5. Race 
a. White 
b. Black or African American 
c. Asian 
d. Native Hawaiian or Other Pacific Islander 
e. Native American/Alaska Native 
f. Biracial 
g. Other: __________________________ 
 
6. Year in school 
a. Freshman (1st year) 
b. Sophomore (2nd year) 
c. Junior (3rd year) 
d. Senior (4th year) 
e. Other: __________________________ 
 
7. Current GPA: _____________ 
 
8. Number of courses enrolled in this semester: _____________ 
 
9. Major: __________________________ 
 
10. Living Status 
a. On-campus dorm 
b. Greek-affiliated house 
c. Off-campus apartment or house 
d. Other: __________________________ 
 
 
 
11. Do you live: 
a. With friends 
b. With family 
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c. By yourself 
 
12. Indicate which of the following applies to you: 
a. I have the University of Mississippi’s student health insurance. 
b. I have health insurance through the state’s Children’s Health Insurance Program 
(CHIP). 
c. I am on my parents’ or another guardian’s health insurance. 
d. I do not have health insurance. 
13. Please indicate how many days you have used each of the following substances in the 
past year. Also, please indicate if you have EVER used the substance in your lifetime 
(SELECT THE APPROPRIATE BOX FOR EACH QUESTION.)  
 
 How often did you use this substance in the PAST 
YEAR? 
Have you 
EVER used 
this 
substance in 
your 
lifetime? 
 
Never 
Less 
than 
monthly 
Monthly Weekly 
Daily/Almost 
daily 
Yes No 
a. Alcohol 1 2 3 4 5 1 2 
b. Caffeine 1 2 3 4 5 1 2 
c. Cigarettes or 
other tobacco 
1 2 3 4 5 1 2 
d. Marijuana (pot, 
weed), hashish 
(hash) 
1 2 3 4 5 1 2 
e. Cocaine (crack, 
coke, rock) 
1 2 3 4 5 1 2 
f. Heroin 1 2 3 4 5 1 2 
g. 
Methamphetamine 
(crank, ice, meth) 
1 2 3 4 5 1 2 
h. Hallucinogens 
(LSD, mescaline, 
peyote, mushrooms, 
psilocybin, etc.) 
1 2 3 4 5 1 2 
i. PCP (angel dust) 
or Ketamine (“K”) 
1 2 3 4 5 1 2 
j. Ecstasy (X), GHB 
(Liquid X), or 
Rohypnol (roofie) 
1 2 3 4 5 1 2 
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1.  Do you have or have you ever had any of the following medical conditions? 
 
        Current?           Approximate  
Date of Diagnosis 
 
a. Heart Attack     yes no  __________  ____________ 
b. Angina (chest pain on exertion) yes no  __________  ____________ 
c. Irregular Heart Beat  yes no  __________  ____________  
d. Other Heart Problems     yes no  __________  ____________ 
e. Stroke    yes no  __________  ____________ 
f. Dizziness/Fainting Spells yes no  __________  ____________ 
g. High Blood Pressure  yes no  __________  ____________ 
h. High Cholesterol  yes no  __________  ____________ 
i. Thyroid Problems  yes no  __________  ____________ 
j. Cancer    yes no  __________  ____________ 
k. Kidney Problems  yes no  __________  ____________ 
l. Liver Problems   yes no  __________  ____________ 
m. Gout    yes no  __________  ____________  
n. Diabetes   yes no  __________  ____________ 
o. Emotional/Psychiatric Problems yes no  __________  ____________ 
p. Drug/Alcohol Problems  yes no  __________  ____________ 
q. Arthritis   yes no  __________  ____________ 
r. Emphysema   yes no  __________  ____________ 
s. Seizure Disorder  yes no  __________  ____________ 
t. Head injury with  
              loss of consciousness  yes no  __________  ____________ 
u. Cognitive impairment  yes no  __________  ____________ 
v. Respiratory or Lung Problem   
 (e.g., Asthma, Bronchitis) yes no  __________  ____________ 
w.        Immune disorder  yes no  __________  ____________ 
 
2.  If you answered ″yes″ to any of the above medical conditions, please describe: 
          
Problem:   _________________________________________________________  
         Treatment Received: _________________________________________ 
          
Problem:  _________________________________________________________ 
         Treatment Received: _________________________________________ 
          
Problem:  _________________________________________________________ 
         Treatment Received: _________________________________________ 
 
3. Do you have a personal physician?          YES NO 
If yes, when was your last visit? ________________  
 
4.  Do you have a personal psychiatrist?      YES NO 
If yes, when was your last visit? ________________ 
 
5.  Have you ever been in therapy?       YES NO 
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5a. If yes, what was the therapy for (e.g., stress, depression, anxiety, anger)? 
________________________________________________________________________ 
 
5b. Are you currently in therapy?       YES NO 
 
5c. If no, when were you in therapy? 
________________________________________________________________________ 
 
6. Please list all medications that you are currently taking on a regular basis: 
MEDICATION   REASON FOR TAKING 
_____________________  _______________________ 
_____________________  _______________________ 
_____________________  _______________________ 
_____________________  _______________________ 
 
7. Have you ever taken any medication for mood?  
YES     NO 
If yes, please list which medication(s):  
Medication:___________________ Dose: ____________________  
Medication:___________________ Dose: ____________________ 
Medication:___________________ Dose: ____________________ 
Medication:___________________ Dose: ____________________  
 
8.  Do you or have you had a prescription for stimulants, sedatives, or opioid painkillers? 
YES  NO  
If yes,  
What stimulant? __________________________  Dose: ________________ 
What sedative? ___________________________  Dose: ________________ 
What opioid painkiller? ____________________  Dose: ________________ 
 
8a. Do you have a current (or have you in the past year) prescription?  YES  NO 
 
8b. What were the doctor’s instructions? 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
 
8c. Do you take the medication as prescribed (e.g., dose, frequency)?  YES  NO  
 
8d. How do you use the 
medication?
______________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
9. Please list any herbal or over-the-counter medications that you take regularly: 
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________________________________________________________________________ 
________________________________________________________________________ 
 
10. Please list any operations/surgeries that you have had: 
  
Procedure:___________________________  Date:_____________ 
 Procedure:___________________________  Date:_____________ 
Procedure:___________________________  Date:_____________ 
 
11.  Is there anything else about your health status that you think might be important or useful 
to tell us?         YES NO  
 
If yes, please explain: 
______________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
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APPENDIX K: GROUP ASSIGNMENT FORM 
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#1 NOT 
endorsed
No use
#1 endorsed
#s 2, 3, or 4 = YES
#5 = social, 
academic, or 
coping is selected
#6 = anything 
other than 0
#8 = YES
NMUPD
Drug Group
#s 2-4 = NO
#8 on 
Health 
Questionnai
re = YES
Medical Use
Non-Drug 
Use Group
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Table 1. Point-Biserial Correlations of NMUPD and Study Variables 
 
 1 2 3 4 5 6 7 8 
1. NMUPD   –        
2. ASI-3 .030 –       
3. DASS-21-A  .120 .363*** –      
4. DERS-Impulse .132 .309*** .559*** –     
5. DTS -.103 -.465*** -.405*** -.573*** –    
6. Quit latency -.046 -.004 -.135 -.147* .060 –   
7. AUDIT .401*** .058 .094 .061 -.050 -.198** –  
8. Illicit drug use .373*** .077 .183* .096 -.120 -.075 .371*** – 
Mean – 15.97 1.89 11.77 48.66 63.24 2.54 0.33 
SD – 4.90 3.34 5.10 12.50 80.46 3.16 0.86 
n 184 184 184 184 184 180 184 168 
Note. ASI-3 = Anxiety Sensitivity Index – 3; AUDIT = Alcohol Use Disorders Identification Test; 
DASS-21-A = Depression Anxiety Stress Scale – 21 – Anxiety subscale; DERS-Impulse = 
Difficulties in Emotion Regulation Scale – Impulse subscale; DTS = Distress Tolerance Scale; 
NMUPD = nonmedical use of prescription drugs; Quit latency = quit latency of Mirror Tracing 
Persistence Task in seconds. 
*p < .05, **p < .01, ***p < .001 
 
 
 
8
7
  
 
Table 2. Between Group Differences on Study Variables  
 
               NMUPD                        Non-NMUPD    
 M SD n M SD n d 95% CI for 
Mean 
Difference 
t p df 
ASI-3  16.16 4.51 69 15.86 5.14 115 0.06 [-1.78 – 1.18] -0.399 .690 182 
DASS-21-
Anxiety  
2.41 3.81 69 1.58 2.99 115 0.24 [-1.77 – 1.18] -1.533 .128 118 
DERS-
Impulse 
12.64 5.71 69 11.25 4.65 115 0.27 [-2.91 – 0.14] -1.793 .075 182 
DTS 47.00 13.10 69 49.66 12.07 115 0.21 [-1.09 – 6.41] 1.402 .163 182 
Quit 
latency 
58.46 72.28 68 66.14 85.23 112 0.10 [-16.77 – 32.13] 0.620 .536 178 
CSSEC 405.04 181.39 69 415.83 182.98 115 0.06 [-44.02 – 65.58] 0.388 .698 182 
Diversity of 
drug use 
2.14 1.67 64 0.71 0.97 103 1.05 [-1.83 – -1.03] -7.020 < .001 165 
AUDIT 4.17 3.55 69 1.57 2.44 115 0.86 [-3.57 – -1.65] -5.393 < .001 106.80 
Poly-
substance 
use 
0.41 0.50 68 0.05 0.21 115 0.97 [-0.49 – -0.24] -5.838 < .001 80.72 
Note. ASI-3 = Anxiety Sensitivity Index – 3; AUDIT = Alcohol Use Disorders Identification Test; CSSEC = College 
Student Stressful Event Checklist; DASS-21-A = Depression Anxiety Stress Scale – 21 – Anxiety subscale; DERS-
Impulse = Difficulties in Emotion Regulation Scale – Impulse subscale; DTS = Distress Tolerance Scale; NMUPD = 
nonmedical use of prescription drugs; Quit latency = quit latency of Mirror Tracing Persistence Task in seconds. 
Diversity of drug use includes alcohol and illicit drugs and excludes tobacco and prescription drugs. 
 
 
 
8
8
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Figure 1. Conceptual diagram of the proposed multiple parallel mediation model 
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Figure 2. Multiple mediation model of the relation between anxiety and NMUPD, with self-
reported anxiety sensitivity, distress tolerance, and emotion-driven impulse control difficulties. 
Note. The unstandardized regression coefficients for each path of the model are reported. 
*p < .001 
 
 
 
 
 
 
 
NMUPD Anxiety 
Anxiety sensitivity 
Distress tolerance 
Emotion-driven 
impulse control 
difficulties 
.0652 
Conditional Indirect Effects: Anxiety sensitivity (-.0098), distress tolerance 
(.0131), and Emotion-driven impulse control difficulties (.0258) 
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Figure 3. Multiple mediation model of the relation between anxiety and NMUPD, with self-
reported anxiety sensitivity and emotion-driven impulse control difficulties, and behaviorally 
measured distress tolerance.  
Note. The unstandardized regression coefficients for each path of the model are reported. 
*p < .001 
 
NMUPD Anxiety 
Anxiety Sensitivity 
Distress Tolerance 
Emotion-driven 
impulse control 
difficulties 
.0369 
Conditional Indirect Effects: Anxiety sensitivity (-.0082), distress tolerance via 
latency to quit (.0018), and Emotion-driven impulse control difficulties (.0433) 
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